Vaccination Against COVID-19 in a Network of Hemodialysis Units in Portugal : A Promising Experience
INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) seriously affected Portugal, particularly in the elderly population with a high number of comorbidities, including patients with chronic kidney disease in stage 5 (CKD-5D) undergoing a regular dialysis program. The aims of this study were to identify the impact of vaccination on the incidence of new daily cases and mortality in the CKD-5D population.
MATERIAL AND METHODS: Prospective, observational study, involving patients with CKD-5D from 38 NephroCare clinics, Portugal. Daily SARS-CoV-2 infections and mortality among these patients was compared with the incidence in the general population. Three periods were analysed: before vaccination, during the vaccination process, and a third period after complete vaccination with the Pfizer-BioNTech' Comirnaty® vaccine. The primary outcome was infection by the SARS-CoV-2 virus and the secondary outcome was death associated with the infection.
RESULTS: A total of 4617 patients (average of 69.37 years of age) were analysed. During the first period, there was a significantly higher COVID-19 incidence of 14.9% in patients with CKD-5D compared with the general population (7.9%; p < 0.001). During the fifteen days after the complete vaccination, results reverted to a significant decrease in COVID-19 cases was observed (p < 0.001). The mortality rate among CKD-5D was significantly higher than in the general population (p < 0.001).
DISCUSSION: A high incidence rate of infection was observed in CKD-5D patients, probably due to several factors such as advanced age, number of comorbidities, inability to remain in confinement, among others. After vaccination there was a significant reduction of new cases.
CONCLUSION: Vaccination significantly reduced SARS-CoV-2 infection in patients with CKD-5D.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Acta medica portuguesa - 35(2022), 5 vom: 02. Mai, Seite 336-342 |
| Sprache: |
Portugiesisch |
|---|
| Beteiligte Personen: |
Fazendeiro Matos, João [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 26.10.2022 Date Revised 26.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.20344/amp.16250 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332804208 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332804208 | ||
| 003 | DE-627 | ||
| 005 | 20231225220329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||por c | ||
| 024 | 7 | |a 10.20344/amp.16250 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332804208 | ||
| 035 | |a (NLM)34742362 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a por | ||
| 100 | 1 | |a Fazendeiro Matos, João |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccination Against COVID-19 in a Network of Hemodialysis Units in Portugal |b A Promising Experience |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2022 | ||
| 500 | |a Date Revised 26.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) seriously affected Portugal, particularly in the elderly population with a high number of comorbidities, including patients with chronic kidney disease in stage 5 (CKD-5D) undergoing a regular dialysis program. The aims of this study were to identify the impact of vaccination on the incidence of new daily cases and mortality in the CKD-5D population | ||
| 520 | |a MATERIAL AND METHODS: Prospective, observational study, involving patients with CKD-5D from 38 NephroCare clinics, Portugal. Daily SARS-CoV-2 infections and mortality among these patients was compared with the incidence in the general population. Three periods were analysed: before vaccination, during the vaccination process, and a third period after complete vaccination with the Pfizer-BioNTech' Comirnaty® vaccine. The primary outcome was infection by the SARS-CoV-2 virus and the secondary outcome was death associated with the infection | ||
| 520 | |a RESULTS: A total of 4617 patients (average of 69.37 years of age) were analysed. During the first period, there was a significantly higher COVID-19 incidence of 14.9% in patients with CKD-5D compared with the general population (7.9%; p < 0.001). During the fifteen days after the complete vaccination, results reverted to a significant decrease in COVID-19 cases was observed (p < 0.001). The mortality rate among CKD-5D was significantly higher than in the general population (p < 0.001) | ||
| 520 | |a DISCUSSION: A high incidence rate of infection was observed in CKD-5D patients, probably due to several factors such as advanced age, number of comorbidities, inability to remain in confinement, among others. After vaccination there was a significant reduction of new cases | ||
| 520 | |a CONCLUSION: Vaccination significantly reduced SARS-CoV-2 infection in patients with CKD-5D | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 Vaccines | |
| 650 | 4 | |a Hemodialysis | |
| 650 | 4 | |a Portugal | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Peralta, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Felix, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Ponce, Pedro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta medica portuguesa |d 1993 |g 35(2022), 5 vom: 02. Mai, Seite 336-342 |w (DE-627)NLM000463329 |x 1646-0758 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:5 |g day:02 |g month:05 |g pages:336-342 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20344/amp.16250 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 5 |b 02 |c 05 |h 336-342 | ||